JONATHAN MOSS, MD
Anesthesiologist Assistant at Harvester Dr, Willowbrook, IL

2008019, Aug 14, 2008

May 6, 2006

11/914984

John C. Alverdy - Glenview IL, US
Jonathan Moss - Chicago IL, US
Mark W. Lingen - Oak Park IL, US
Patrick A. Singleton - Chicago IL, US
Joe G.N. Garcia - Chicago IL, US

A61K 31/485, A61K 31/445, A61P 31/00, A61P 17/00

514282, 514331

The invention provides prophylactic and therapeutic methods for administering a μ-opioid receptor antagonist to treat cell barrier diseases and disorders, such as endothelial and epithelial cell barrier diseases and disorders. The diseases or disorders may amenable to the methods include inflammation, such as acute lung injury, atherosclerosis, gut-derived sepsis, a burn injury, neonatal necrotizing enterocolitis, severe neutropenia, toxic colitis, inflammatory bowel disease, enteropathy, transplant rejection, pouchitis, pig belly (pig-bel), -mediated opthalmologic infection, -mediated otologic infection and -mediated cutaneous infection. More generally, epithelial cell barrier disorders are contemplated as amenable to the prophylactic and therapeutic methods. The diseases and disorders may be induced by microbial pathogens, including bacterial pathogens such as . The invention further provides prophylactic and therapeutic methods for inhibiting the expression of bacterial PA-I lectin/adhesin and for inhibiting bacterial MvfR activity levels. Also provided is a method of using a μ-opioid receptor antagonist in the manufacture of a medicament for use in the methods described herein.

6274591, Aug 14, 2001

Jul 22, 1998

9/120703

Joseph F. Foss - Chicago IL
Michael F. Roizen - Chicago IL
Jonathan Moss - Chicago IL
William Drell - San Diego CA

A61K 31448

514282

A method for preventing or treating the opioid induced side effect, inhibition of gastrointestinal motility is disclosed. The method comprises administering methylnaltrexone or another quaternary derivative of noroxymorphone to a patient prior to the administration of an opioid or after the onset of side effects induced by the administration of an opioid, wherein the methylnaltrexone or quaternary derivative is administered orally in an enterically coated form.

2003018, Oct 2, 2003

Feb 4, 2003

10/357669

Joseph Foss - Chicago IL, US
Michael Roizen - Chicago IL, US
Jonathan Moss - Chicago IL, US
William Drell - San Diego CA, US

A61K031/485

514/282000

A method of preventing or treating an opioid-induced side effect in a patient who has been chronically taking opioids, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or treat the side effect in the patient, but which amount would be insufficient to treat a patient with the same opioid-induced side effect who had not chronically been administered opioids.

5972954, Oct 26, 1999

Nov 3, 1997

8/962742

Joseph F. Foss - Chicago IL
Michael F. Roizen - Chicago IL
Jonathan Moss - Chicago IL
William Drell - San Diego CA

Arch Development Corporation - Chicago IL
UR Labs, Inc. - Reno NV

A61K 31485

514282

A method for preventing or treating opioid induced side effects including dysphoria, pruritus and urinary retention and non-opioid induced changes in gastrointestinal motility. The method comprises administering methylnaltrexone or another quaternary derivative of noroxymorphone to a patient prior to the administration of an opioid or after the onset of side effects induced by the administration of an opioid, wherein the methylnaltrexone or quaternary derivative is administered by the route selected from the group consisting of intravenous, intramuscular, transmucosal, transdermal, and oral administration, preferably administered orally in an enterically coated form.

2005001, Jan 20, 2005

Aug 13, 2004

10/917412

Jonathan Moss - Chicago IL, US

B68B001/06

119651000

Systems and methods are described for using methylnaltrexone to treat or prevent inhibition of gastrointestinal motility in equines. A method for preventing or treating opioid-induced and non-opioid-induced gastrointestinal dysfunction includes administering a quaternary derivative of noroxymorphone, preferably methylnaltrexone, to an equine before or after the onset of the gastrointestinal dysfunction.

2005004, Mar 3, 2005

Oct 12, 2004

10/962729

Joseph Foss - Chicago IL, US
Michael Roizen - Chicago IL, US
Jonathan Moss - Chicago IL, US
William Drell - San Diego CA, US

A61K009/24, A61K031/485

424471000, 424472000, 514282000

A composition for preventing or treating the opioid induced side effect, inhibition of gastrointestinal motility is disclosed. The composition comprises methylnaltrexone or another quaternary derivative of noroxymorphone administered to a patient prior to the administration of an opioid or after the onset of side effects induced by the administration of an opioid, wherein the methylnaltrexone or quaternary derivative is administered orally in an enterically coated form.

2012031, Dec 13, 2012

May 30, 2012

13/483932

John C. Alverdy - Glenview IL, US
Jonathan Moss - Chicago IL, US
Mark W. Lingen - Oak Park IL, US
Patrick A. Singleton - Chicago IL, US
Joe G.N. Garcia - Chicago IL, US

THE UNIVERSITY OF CHICAGO - CHICAGO IL

A61K 31/485, A61P 1/00

514282

The invention provides prophylactic and therapeutic methods for administering a μ-opioid receptor antagonist, e.g., N-methylnaltrexone or a salt thereof, to treat cell barrier diseases and disorders, such as endothelial and epithelial cell barrier diseases and disorders, e.g., inflammatory bowel disease. Methods of reducing the symptoms of inflammatory bowel disease and the risk of developing inflammatory bowel disease are also provided.

2003015, Aug 21, 2003

Feb 4, 2003

10/358560

Joseph Foss - Chicago IL, US
Michael Roizen - Chicago IL, US
Jonathan Moss - Chicago IL, US
William Drell - San Diego CA, US

A61K031/485

514/282000

A method of preventing or treating an opioid-induced side effect in a patient who has been chronically taking opioids, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or treat the side effect in the patient, but which amount would be insufficient to treat a patient with the same opioid-induced side effect who had not chronically been administered opioids.

2012027, Nov 1, 2012

Jun 26, 2012

13/533578

Joseph F. Foss - Chicago IL, US
Michael F. Roizen - Chicago IL, US
Jonathan Moss - Chicago IL, US
William Drell - San Diego CA, US

The University of Chicago - Chicago IL

A61K 31/485, A61P 1/00

514282

A method of preventing or treating constipation in a patient who has been chronically taking opioids, the method comprising administering a quaternary derivative of noroxymorphone in an amount sufficient to prevent or treat the side effect in the patient, but which amount would be insufficient to treat a patient with the same opioid-induced side effect who had not chronically been administered opioids.